Literature DB >> 22285998

Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1.

A R Soliera1, S A Mariani, A Audia, M R Lidonnici, S Addya, G Ferrari-Amorotti, S Cattelani, G Manzotti, V Fragliasso, L Peterson, G Perini, T L Holyoake, B Calabretta.   

Abstract

Expression of the transcription repressor Gfi-1 is required for the maintenance of murine hematopoietic stem cells. In human cells, ectopic expression of Gfi-1 inhibits and RNA interference-mediated Gfi-1 downregulation enhances proliferation and colony formation of p210BCR/ABL expressing cells. To investigate the molecular mechanisms that may explain the effects of perturbing Gfi-1 expression in human cells, Gfi-1-regulated genes were identified by microarray analysis in K562 cells expressing the tamoxifen-regulated Gfi-1-ER protein. STAT 5B and Mcl-1, two genes important for the proliferation and survival of hematopoietic stem cells, were identified as direct and functionally relevant Gfi-1 targets in p210BCR/ABL-transformed cells because: (i) their expression and promoter activity was repressed by Gfi-1 and (ii) when constitutively expressed blocked the proliferation and colony formation inhibitory effects of Gfi-1. Consistent with these findings, genetic or pharmacological inhibition of STAT 5 and/or Mcl-1 markedly suppressed proliferation and colony formation of K562 and CD34+ chronic myelogenous leukemia (CML) cells. Together, these studies suggest that the Gfi-1STAT 5B/Mcl-1 regulatory pathway identified here can be modulated to suppress the proliferation and survival of p210BCR/ABL-transformed cells including CD34+ CML cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285998      PMCID: PMC7416842          DOI: 10.1038/leu.2012.19

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  41 in total

1.  Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells.

Authors:  Hui Zeng; Raif Yücel; Christian Kosan; Ludger Klein-Hitpass; Tarik Möröy
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

2.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Authors:  Mai Nguyen; Richard C Marcellus; Anne Roulston; Mark Watson; Lucile Serfass; S R Murthy Madiraju; Daniel Goulet; Jean Viallet; Laurent Bélec; Xavier Billot; Stephane Acoca; Enrico Purisima; Adrian Wiegmans; Leonie Cluse; Ricky W Johnstone; Pierre Beauparlant; Gordon C Shore
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

3.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

4.  Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation.

Authors:  Karen Keeshan; Giorgia Santilli; Francesca Corradini; Danilo Perrotti; Bruno Calabretta
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

5.  The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells.

Authors:  Francesco D'Alo'; Lisa M Johansen; Erik A Nelson; Hanna S Radomska; Erica K Evans; Pu Zhang; Claus Nerlov; Daniel G Tenen
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

6.  The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest.

Authors:  Christine Müller; Cornelis F Calkhoven; Xiaojing Sha; Achim Leutz
Journal:  J Biol Chem       Date:  2003-12-04       Impact factor: 5.157

7.  Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1.

Authors:  Marc A Kerenyi; Florian Grebien; Helmuth Gehart; Manfred Schifrer; Matthias Artaker; Boris Kovacic; Hartmut Beug; Richard Moriggl; Ernst W Müllner
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

Review 8.  Disruption of differentiation in human cancer: AML shows the way.

Authors:  Daniel G Tenen
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

9.  CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors.

Authors:  H S Radomska; C S Huettner; P Zhang; T Cheng; D T Scadden; D G Tenen
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

Review 10.  Transcriptional dysregulation during myeloid transformation in AML.

Authors:  T Pabst; B U Mueller
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

View more
  21 in total

1.  Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Valentina Minieri; Marco De Dominici; Patrizia Porazzi; Samanta A Mariani; Orietta Spinelli; Alessandro Rambaldi; Luke F Peterson; Pierluigi Porcu; Marja T Nevalainen; Bruno Calabretta
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

2.  Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.

Authors:  Xianping Shi; Xin Chen; Xiaofen Li; Xiaoying Lan; Chong Zhao; Shouting Liu; Hongbiao Huang; Ningning Liu; Siyan Liao; Wenbin Song; Ping Zhou; Shunqing Wang; Li Xu; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Clin Cancer Res       Date:  2013-12-12       Impact factor: 12.531

Review 3.  Selecting the best frontline treatment in chronic myeloid leukemia.

Authors:  Musa Yilmaz; Yasmin Abaza; Elias Jabbour
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

4.  Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.

Authors:  Zhiyong Liao; Lei Gu; Jenny Vergalli; Samanta A Mariani; Marco De Dominici; Ravi K Lokareddy; Ayush Dagvadorj; Puranik Purushottamachar; Peter A McCue; Edouard Trabulsi; Costas D Lallas; Shilpa Gupta; Elyse Ellsworth; Shauna Blackmon; Adam Ertel; Paolo Fortina; Benjamin Leiby; Guanjun Xia; Hallgeir Rui; David T Hoang; Leonard G Gomella; Gino Cingolani; Vincent Njar; Nagarajan Pattabiraman; Bruno Calabretta; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2015-05-29       Impact factor: 6.261

5.  Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Authors:  L Schafranek; E Nievergall; J A Powell; D K Hiwase; T Leclercq; T P Hughes; D L White
Journal:  Leukemia       Date:  2014-05-12       Impact factor: 11.528

6.  Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.

Authors:  J G Harb; P Neviani; B J Chyla; J J Ellis; G J Ferenchak; J J Oaks; C J Walker; P Hokland; D C Roy; M A Caligiuri; G Marcucci; C S Huettner; D Perrotti
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528

7.  TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Authors:  David T Yeung; Michael P Osborn; Deborah L White; Susan Branford; Jodi Braley; Alan Herschtal; Michael Kornhauser; Samar Issa; Devendra K Hiwase; Mark Hertzberg; Anthony P Schwarer; Robin Filshie; Christopher K Arthur; Yiu Lam Kwan; Judith Trotman; Cecily J Forsyth; John Taper; David M Ross; Jennifer Beresford; Constantine Tam; Anthony K Mills; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2014-12-17       Impact factor: 22.113

8.  GFI1 is repressed by p53 and inhibits DNA damage-induced apoptosis.

Authors:  Pei Du; Fangqiang Tang; Yaling Qiu; Fan Dong
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

9.  Expression of p89(c-Mybex9b), an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells.

Authors:  G Manzotti; S A Mariani; F Corradini; R Bussolari; V Cesi; J Vergalli; G Ferrari-Amorotti; V Fragliasso; A R Soliera; S Cattelani; G Raschellà; T L Holyoake; B Calabretta
Journal:  Blood Cancer J       Date:  2012-05-11       Impact factor: 11.037

10.  Lymphoid progenitor cells from childhood acute lymphoblastic leukemia are functionally deficient and express high levels of the transcriptional repressor Gfi-1.

Authors:  Jessica Purizaca; Adriana Contreras-Quiroz; Elisa Dorantes-Acosta; Eduardo Vadillo; Lourdes Arriaga-Pizano; Silvestre Fuentes-Figueroa; Horacio Villagomez-Barragán; Patricia Flores-Guzmán; Antonio Alvarado-Moreno; Hector Mayani; Isaura Meza; Rosaura Hernandez; Sara Huerta-Yepez; Rosana Pelayo
Journal:  Clin Dev Immunol       Date:  2013-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.